Some asthma and allergy medication will now require a stronger warning label, the U.S. Food and Drug Administration announced Wednesday. The medication, generically known as montelukast, but sold ...
A Boxed Warning or “Black Box Warning,” the most prominent and serious of FDA warnings about prescription drugs, will adorn packages of asthma and allergy medicine montelukast (brand name: Singulair), ...
ORLANDO -- Neuropsychiatric events among children after starting montelukast (Singulair) for allergy and asthma treatment were more likely for those who had a history of comorbid psychiatric ...
Despite concerns about its possible side effects, Western Pennsylvania doctors say some patients can remain on Singulair to relieve asthma or allergy symptoms. But in most cases, the doctors say they ...
The FDA announced they would start requiring a boxed warning for Singulair, also known as montelukast, back in March An FDA announcement regarding a new warning for a common allergy and asthma ...
* FDA- FOR RHINITIS, DETERMINED MONTELUKAST SHOULD BE RESERVED FOR THOSE WHO ARE NOT TREATED EFFECTIVELY WITH/ CANNOT TOLERATE OTHER ALLERGY MEDICINES * FDA- FOR ASTHMA PATIENTS , RECOMMEND HEALTH ...
Two advisory committees of the US Food and Drug Administration (FDA) met jointly to discuss a safety review of neuropsychiatric events in children taking montelukast (Singulair, Merck) for asthma and ...
Australia's Therapeutic Goods Administration (TGA) recently issued a safety alert requiring extra warnings to be included with the asthma and hay fever drug montelukast. The warnings are for users and ...
A Boxed Warning or “Black Box Warning,” the most prominent and serious of FDA warnings about prescription drugs, will adorn packages of asthma and allergy medicine montelukast (brand name: Singulair), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback